Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
Jazz Pharmaceuticals reported Q1 2026 revenue of $1.07 billion, up 19% year-over-year, with non-GAAP EPS of $6.34 versus a prior-year loss. Key growth drivers included Xywav (up 18% to $408M) and Epidiolex (up 15% to $250M), while the oncology portfolio gained momentum with Zepzelca up 60%. The company announced a major regulatory milestone, with the FDA granting Priority Review to zanidatamab for 1L HER2+ GEA with a PDUFA date of August 25, 2026.
Key figures
- Eps
- 4.43
- Guidance
- Reaffirmed 2026 total revenues of $4.25B-$4.50B
- Revenue Yoy
- 19%
- Drug Name
- zanidatamab
- Pdufa date
- August 25, 2026
- Total cash
- 2900000000
- Non gaap eps
- 6.34
- Long term debt
- 5400000000
- Operating cash flow
- 408000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.